Generated by AI
OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.
The latest articles about OSTX.
Detailed price information for Axalta Coating Systems Ltd (AXTA-N) from The Globe and Mail including charting and trades.
Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.
Detailed price information for Evommune Inc (EVMN-N) from The Globe and Mail including charting and trades.
Detailed price information for Concentra Group Holdings Parent Inc (CON-N) from The Globe and Mail including charting and trades.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about OSTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.